Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 9Not yet recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms 1Genital Neoplasms, Male 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adrenal Cortex Hormones × 1 year × Clear all
NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis

Phase 1/2 Active not recruiting
152 enrolled
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡